These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 4438251)

  • 1. [Myeloproliferative disorders (author's transl)].
    Rousso C
    Schweiz Rundsch Med Prax; 1974 Nov; 63(45):1335-7. PubMed ID: 4438251
    [No Abstract]   [Full Text] [Related]  

  • 2. Introduction: overview of chronic myeloproliferative disorders.
    Tefferi A
    Semin Hematol; 1999 Jan; 36(1 Suppl 2):1-2. PubMed ID: 9930549
    [No Abstract]   [Full Text] [Related]  

  • 3. Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan.
    Nielsen I; Hasselbalch HC
    Am J Hematol; 2003 Sep; 74(1):26-31. PubMed ID: 12949887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Acute myeloproliferative syndrome after alkylating agent treatment in a case of multiple myeloma].
    Gardella S; Cervantes F; Bladé J; Brugués R; Rozman C
    Med Clin (Barc); 1982 Sep 1-15; 79(4):185-8. PubMed ID: 7144293
    [No Abstract]   [Full Text] [Related]  

  • 5. [Therapeutic results of chronic leukemia and other myeloproliferative syndrome with streptonigrin in 92 cases (author's transl)].
    Wang YL
    Zhonghua Nei Ke Za Zhi; 1980 May; 19(3):223-5. PubMed ID: 7227060
    [No Abstract]   [Full Text] [Related]  

  • 6. [Relationship between microvascular occlusion-like symptoms and spontaneous platelet aggregation in chronic myeloproliferative diseases (author's transl)].
    Tanoue K; Nakazawa M; Nakamura H; Nagasawa T; Yoda Y; Abe T; Ijima H; Iyori S
    Rinsho Ketsueki; 1981 Jul; 22(7):1123-9. PubMed ID: 7328769
    [No Abstract]   [Full Text] [Related]  

  • 7. [Evaluation of the effects of the gammaglobulin preparation on the infections in patients with hematological malignancy (author's transl)].
    Haneda Y; Fukushi G; Ishizawa M; Ohmi T; Kimura A; Kawamura S; Chiba Y
    Rinsho Ketsueki; 1980 Aug; 21(8):1156-61. PubMed ID: 6160269
    [No Abstract]   [Full Text] [Related]  

  • 8. [A "myeloproliferative syndrome" of long duration (author's transl)].
    Kühböck J; Peskar BM; Vormittag W
    Med Klin; 1974 Mar; 69(10):423-6. PubMed ID: 4524608
    [No Abstract]   [Full Text] [Related]  

  • 9. Mutant molecules of interest in myeloproliferative neoplasms: introduction.
    Tefferi A
    Acta Haematol; 2008; 119(4):192-3. PubMed ID: 18566535
    [No Abstract]   [Full Text] [Related]  

  • 10. [Leukocyte alkaline phosphatase and glucose-6-phosphate-dehydrogenase of the erythrocytes in differential diagnosis of chronic myeloproliferative diseases (author's transl)].
    Hennemann HH; Schief A
    Med Klin; 1974 Aug; 69(34):1359-63. PubMed ID: 4530151
    [No Abstract]   [Full Text] [Related]  

  • 11. [Toward discussion on the modern theory of hematopoiesis and classification of hemoblastoses].
    Krylov AA; Dmitriev VI
    Probl Gematol Pereliv Krovi; 1974 Oct; 19(10):47-50. PubMed ID: 4610555
    [No Abstract]   [Full Text] [Related]  

  • 12. [Lycurim in the treatment of patients with chronic lymphocytic leukemia (author's transl)].
    Janicki K; Skotnicki AS; Blicharski J; Kwiatkowski A; Sliwczyńska-Dura B; Lisiewicz J
    Przegl Lek; 1980; 37(4):429-35. PubMed ID: 6996043
    [No Abstract]   [Full Text] [Related]  

  • 13. [Introduction to the study of chronic myeloproliferative syndromes].
    Bernard J; Tanzer J
    Rev Prat; 1973 Oct; 23(45):3915-6. PubMed ID: 4801741
    [No Abstract]   [Full Text] [Related]  

  • 14. Defining targets in myeloproliferative disorders: reflecting on what is important.
    Griesshammer M
    Hematol Oncol; 2009 Jun; 27 Suppl 1():2-4. PubMed ID: 19468984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful treatment with imatinib mesylate in a case of chronic myeloproliferative disorder with a t(5;12)(q33;p13.1) without eosinophilia.
    Nadal N; Flandrin P; Cornillon J; Delabesse E; Mauvieux L; Olaru D; Morel S; Campos L
    Cancer Genet Cytogenet; 2006 Sep; 169(2):174-5. PubMed ID: 16938578
    [No Abstract]   [Full Text] [Related]  

  • 16. [Classification of hemoblastoses: diagnostic and therapeutic signs].
    Cimino R
    Minerva Stomatol; 1980; 29(2):127-9. PubMed ID: 6935503
    [No Abstract]   [Full Text] [Related]  

  • 17. New perspectives in managing myeloproliferative disorders: focus on the patient.
    Birgegård G
    Hematol Oncol; 2009 Jun; 27 Suppl 1():5-7. PubMed ID: 19468983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The new WHO nomenclature: introduction and myeloid neoplasms.
    Rodak BF; Leclair SJ
    Clin Lab Sci; 2002; 15(1):44-54. PubMed ID: 12778956
    [No Abstract]   [Full Text] [Related]  

  • 19. [In vitro CFU-mix in peripheral blood of myeloproliferative disorders stimulated by serum of aplastic anemia (author's transl)].
    Aoki I; Toyama K; Okamoto S; Young CD
    Rinsho Ketsueki; 1982 Jan; 23(1):46-52. PubMed ID: 6980301
    [No Abstract]   [Full Text] [Related]  

  • 20. [Myeloproliferative disorder with hyperdiploid stemline (47, XY, mar +) (author's transl)].
    Vormittag W; Kühböck J; Peskar BM
    Wien Klin Wochenschr; 1973 Nov; 85(45):747-9. PubMed ID: 4761853
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.